

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gruenberg, M.

Serial No.: 09/824,906

Conf. No. 9764

Filed: April 2, 2001

For: **AUTOLOGOUS IMMUNE CELL  
THERAPY: CELL COMPOSITIONS,  
METHODS AND APPLICATIONS TO  
TREATMENT OF HUMAN DISEASE**

Art Unit: 1644

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, D.C. 20231, on this date.

10/05/01  
Date

Kelly Fischer  
Kelly Fischer

**INFORMATION DISCLOSURE STATEMENT  
IN ACCORDANCE WITH 37 C.F.R. § 1.97-1.98**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed before receipt of a First Office Action on the merits for the above-captioned application, no fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (16 pages) are provided herewith in connection with the above-captioned application. In accordance with 37 C.F.R. §1.98(d), copies of the references listed on the Form PTO-1449 which have been previously provided in connection with applications U.S. Serial No. 08/700,565

**U.S.S.N. 09/824,906**  
**GRUENBERG**  
**Information Disclosure Statement**

which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120, are not provided herewith.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language except for item CX. Item CX (Japanese Patent No. JP 2883201) is in the Japanese language and is supplied with a certified English language translation (item DZ), an English language Derwent abstract describing the subject matter (item EM), and a corresponding International Publication WO 90/05541. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications, which are commonly owned and/or have one or more inventors in common.

<u>U.S.S.N.(App. no.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
08/700,565	07/25/96	500B
09/127,411	07/31/98	500C
09/127,142	07/31/98	500D
09/127,138	07/31/98	500E
09/127,141	07/31/98	500F

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

**U.S.S.N. 09/824,906**  
**GRUENBERG**  
**Information Disclosure Statement**

Applicant respectfully requests that the Examiner review the foregoing reference and it be made of record in the file history of the above-captioned application.

\* \* \*


Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By: \_\_\_\_\_

Stephanie Seidman  
Registration No. 33,779

Attorney Docket No. 24731-500G  
**Address all correspondence to:**  
HELLER, EHRMAN, WHITE & McAULIFFE LLP  
4350 La Jolla Village Drive, Suite 600  
San Diego, CA 92122-1246  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
E-Mail: sseidman@hewm.com

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644
 RECEIVED  
 OCT 10 2001  
 PATENT & TRADEMARK OFFICE  
 CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	3	8	2	1	0	8	7	6/28/74	Knazek <i>et al.</i>	195	127	5/18/72
	AB	3	8	8	3	3	9	3	5/13/75	Knazek <i>et al.</i>	195	1.8	2/11/74
	AC	3	9	9	7	3	9	6	12/14/76	Delente	195	1.8	7/02/73
	AD	4	0	8	7	3	2	7	5/02/78	Feder <i>et al.</i>	195	1.7	4/12/76
	AE	4	2	0	0	6	8	9	4/29/80	Knazek <i>et al.</i>	435	2	8/29/78
	AF	4	2	0	6	0	1	5	6/03/80	Knazek <i>et al.</i>	435	2	8/29/78
	AG	4	2	2	0	7	2	5	09/02/80	Knazek <i>et al.</i>	435	285	4/03/78
	AH	4	3	0	1	2	4	9	11/17/81	Markus <i>et al.</i>	435	235	7/23/80
	AI	4	3	9	1	9	1	2	7/5/83	Yoshida <i>et al.</i>	435	241	9/18/80
	AJ	4	5	4	6	0	8	3	10/08/85	Meyers <i>et al.</i>	435	240	4/22/83
	AK	4	6	2	9	6	8	6	12/16/86	Gruenberg	435	1	06/14/82
	AL	4	6	9	0	9	1	5	09/01/87	Rosenberg	514	2	08/08/85
	AM	4	7	2	2	9	0	2	02/02/88	Harm <i>et al.</i>	435	284	11/04/85
	AN	4	8	0	4	6	2	8	02/14/89	Cracauer <i>et al.</i>	435	240.242	08/19/87
	AO	4	8	0	8	1	5	1	02/28/89	Dunn, Jr. <i>et al.</i>	604	6	04/27/87
	AP	4	8	4	9	3	2	9	07/18/89	Leung <i>et al.</i>	435	2	04/20/87
	AQ	4	8	6	1	5	8	9	08/29/89	Ju	424	93	03/23/87
	AR	4	8	9	4	3	4	2	01/16/90	Guinn <i>et al.</i>	435	291	09/22/86
	AS	4	9	3	7	0	7	1	06/26/90	Cioco <i>et al.</i>	424	85.2	12/29/87
	AT	4	9	7	1	7	9	5	11/20/90	Longenecker <i>et al.</i>	424	93	07/21/88
	AU	4	9	7	3	5	5	8	11/27/90	Wilson <i>et al.</i>	435	240.242	04/28/88
	AV	4	9	9	9	2	9	8	03/12/91	Wolfe <i>et al.</i>	435	240.242	04/27/88
	AW	5	0	0	2	8	7	9	03/26/91	Bowlin <i>et al.</i>	435	71.1	12/05/89

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS  
TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644
 OFFICE OF PATENTS AND PUBLICATIONS FOR  
 APPLICANT'S INFORMATION DISCLOSURE  
 STATEMENT

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AX	5	0	1	5	5	8	5	05/14/91	Robinson	435	240.242	02/23/88
	AY	5	0	4	1	2	8	9	08/20/91	Phillips <i>et al.</i>	424	85.2	11/13/87
	AZ	5	0	5	7	4	2	3	10/15/91	Hiserodt <i>et al.</i>	435	240.23	12/18/87
	BA	5	0	6	1	6	2	0	10/29/91	Tsukamoto <i>et al.</i>	435	7.21	03/30/90
	BB	5	0	6	4	7	6	4	11/12/91	Besnainon <i>et al.</i>	435	285	12/19/89
	BC	5	1	2	3	9	0	1	06/23/92	Carew	604	5	missing
	BD	5	1	2	6	1	3	2	06/30/92	Rosenberg	424	93	08/21/89
	BE	5	1	2	6	2	3	8	06/30/92	Gebhard <i>et al.</i>	435	3	02/15/90
	BF	5	1	4	7	2	8	9	09/15/92	Edelson	604	4	03/29/90
	BG	5	1	4	7	7	8	4	09/15/92	Peault	435	7.24	04/12/90
	BH	5	1	6	2	2	2	5	11/10/92	Sager <i>et al.</i>	435	240.243	07/15/91
	BI	5	1	8	8	9	6	9	02/23/93	Arai <i>et al.</i>	436	548	06/15/89
	BJ	5	1	9	2	5	3	7	03/09/93	Osband	424	85.2	08/19/91
	BK	5	2	0	2	2	5	4	04/13/93	Amiot <i>et al.</i>	435	240.242	10/11/90
	BL	5	2	2	9	1	1	5	07/20/93	Lynch	424	93	07/26/90
	BM	5	2	4	2	6	8	7	09/07/93	Tykocinski <i>et al.</i>	424	93	04/25/91
	BN	5	2	7	7	9	0	7	01/11/94	Loria	424	93	07/24/92
	BO	5	3	1	6	7	6	3	05/31/94	Ochoa <i>et al.</i>	424	85.2	07/10/92
	BP	5	3	2	6	7	6	3	07/05/94	Gluchowski <i>et al.</i>	514	249	01/29/93
	BQ	5	3	7	4	5	4	9	12/20/94	Leung	435	240.2	01/31/91
	BR	5	3	9	9	3	4	6	03/21/95	Anderson <i>et al.</i>	424	93.21	03/30/94
	BS	5	3	9	9	3	4	7	03/21/95	Trentham <i>et al.</i>	424	184.1	09/25/92
	BT	5	4	0	9	8	1	3	04/24/95	Schwartz	435	7.24	09/30/93

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS  
TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	BU	5	4	1	1	7	4	9	05/02/95	Mayo <i>et al.</i>	424	578	12/23/92
	BV	5	4	3	7	9	9	4	08/01/95	Emerson <i>et al.</i>	435	240.2	12/10/93
	BW	5	4	4	3	9	8	3	08/22/95	Ochoa <i>et al.</i>	435	240.2	03/21/88
	BX	5	4	5	9	0	6	9	10/17/95	Palsson <i>et al.</i>	435	289.1	01/06/94
	BY	5	4	6	6	5	7	2	11/14/95	Sasaki <i>et al.</i>	435	2	04/25/94
	BZ	5	4	7	0	7	3	0	11/28/95	Greenberg <i>et al.</i>	435	172.3	08/08/94
	CA	5	4	7	6	9	9	7	12/19/95	Kaneshima <i>et al.</i>	800	2	05/17/94
	CB	5	4	9	8	5	3	7	03/12/96	Bresler <i>et al.</i>	435	235.1	03/09/94
	CD	5	5	1	2	4	4	4	04/30/96	Patard <i>et al.</i>	435	6	11/30/94
	CE	5	5	9	9	7	0	5	02/04/97	Cameron	435	378	11/16/93
	CF	5	6	0	5	8	2	2	02/25/97	Emerson <i>et al.</i>	435	172.3	12/01/94
	CG	5	6	2	2	8	5	7	04/22/97	Goffe	435	378	08/08/95
	CH	5	6	2	7	0	7	0	05/06/97	Gruenberg	435	786.5	07/26/95
	CI	5	6	3	5	3	8	6	06/03/97	Palsson <i>et al.</i>	435	372	11/02/94
	CJ	5	6	3	5	3	8	7	06/03/97	Fei <i>et al.</i>	435	378	04/03/95
	CK	5	6	3	7	4	8	1	06/10/97	Ledbetter <i>et al.</i>	435	69.6	09/13/93
	CL	5	6	4	6	0	4	3	07/08/97	Emerson <i>et al.</i>	435	373	03/10/95
	CM	5	6	5	6	4	2	1	08/12/97	Gebhard <i>et al.</i>	435	3	02/12/91
	CM	5	6	7	6	8	4	9	10/14/97	Sammons <i>et al.</i>	210	806	03/08/95
	CO	5	7	1	8	8	8	3	02/17/98	Harlan <i>et al.</i>	424	9.2	02/17/94
	CP	5	7	2	8	5	8	1	03/17/98	Schwartz <i>et al.</i>	435	385	06/07/95
	CQ	5	7	6	3	2	6	1	06/09/98	Gruenberg	435	286.5	12/05/96
	CR	5	7	6	3	2	6	6	06/09/98	Palsson <i>et al.</i>	435	289.1	11/07/94


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS  
TO TREATMENT OF HUMAN DISEASE

Date mailed:



RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 1 2 2001

TECH CENTER 1600/2900

OCT 1 0 2001

PATENT &amp; TRADEMARK OFFICE

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	CS	5	7	6	6	9	2	0	06/16/98	Babbit <i>et al.</i>	435	240.1	06/06/95
	CT	5	8	1	1	3	0	1	09/22/98	Cameron	435	372	08/07/96
	CU	5	8	5	8	3	5	8	01/12/99	June <i>et al.</i>	424	130.1	06/03/94
	CV	5	9	9	4	1	2	6	11/30/99	Steinman <i>et al.</i>	435	325	06/17/94

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	CW	0	4	0	5	9	7	2	1/2/91	EPO	A1			
	CX	2	8	8	3	2	0	1	04/99	JP	B2		X	
	CY	9	0	0	5	5	4	1	05/31/90	PCT				
	CZ	9	0	1	5	8	7	7	12/27/90	PCT				
	DA	9	1	0	4	3	1	7	04/04/91	PCT				
	DB	9	1	1	8	9	7	2	12/12/91	PCT				
	DC	9	3	1	9	7	6	7	10/14/93	PCT				
	DD	9	4	2	2	4	8	9	10/13/94	PCT				
	DE	9	4	2	3	7	6	0	10/27/94	PCT				
	DF	9	4	2	8	9	1	2	12/22/94	PCT				
	DG	9	4	2	9	4	3	6	12/22/94	PCT				
	DH	9	5	2	9	6	7	3	11/09/95	PCT				
	DI	9	5	3	3	8	2	3	12/14/95	PCT				
	DJ	9	5	3	3	8	2	3	12/14/95	PCT				
	DK	9	6	3	4	9	5	6	11/07/96	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS  
TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	DL	9	6	3	4	9	7	0	11/7/96	PCT				
	DM	9	6	4	0	8	6	0	12/19/96	PCT				
	DN	9	6	4	0	8	7	6	12/19/96	PCT				
	DO	9	7	0	5	2	3	9	2/13/97	PCT				
	DP	9	7	3	1	6	4	7	09/04/97	PCT				
	DQ	9	8	2	5	4	5	7	06/18/98	PCT				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DR	Alberts, B. <i>et al.</i> , " <u>Molecular Biology of the Cell</u> ", 3rd ed., Garland Publishing, Inc., ppp. 1169 (1994)
DS	Autran <i>et al.</i> , A Th0/Th2-like function of CD4 <sup>+</sup> CD7 <sup>-</sup> T helper cells from normal donors and HIV-infected patients, <u>J. Immunol.</u> 154: 1408-1417 (1995)
DT	Bartholeyns <i>et al.</i> , Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer, <u>Anticancer Research</u> 14: 2673-2676 (1994)
DU	Benvenuto <i>et al.</i> , Enhanced production of interferon- $\gamma$ by T lymphocytes cloned from rejected kidney grafts, <u>Transplantation</u> 51: 887-890 (1991)
DV	Benvenuto <i>et al.</i> , Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis, <u>Clin. Exp. Immunol.</u> 84: 97-102 (1991)
DW	Bernhard <i>et al.</i> , Generation of immunostimulatory dendritic cells from human CD34 + hematopoietic progenitor cells of the bone marrow and peripheral blood, <u>Cancer Res.</u> 55: 1099-1104 (1995)
DX	Boiardi <i>et al.</i> , Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients, <u>Cancer Immunol. Immunother.</u> 39: 193-197 (1994)
DY	Brod <i>et al.</i> , Restricted T cell expression of IL-2/Ifn- $\gamma$ mRNA in human inflammatory disease, <u>J. Immunol.</u> 147: 810-815 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DZ	Certified English language translation of the Japanese Patent No. 2883201
EA	Cesano <i>et al.</i> , Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach, <u>J. Clin. Invest.</u> <b>94</b> : 1076-1084 (1994)
EB	Chen <i>et al.</i> , Donor T cells can be induced to grow and survive long term <i>in vivo</i> without previous host immunosuppression, <u>J. Immunol.</u> <b>152</b> : 4767-4774 (1994)
EC	Chen <i>et al.</i> , Regulatory T cell clone induced by oral tolerance: Suppression of autoimmune encephalomyelitis, <u>Science</u> <b>265</b> : 1237-1240 (1994)
ED	Cherwinski <i>et al.</i> , Two types of mouse helper T cell clone, <u>J. Exp. Med.</u> <b>166</b> : 1229-1244 (1987)
EE	Chick <i>et al.</i> , Beta cell culture on synthetic capillaries: An artificial endocrine pancreas, <u>Science</u> <b>187</b> : 847-849 (1975)
EF	Clerici <i>et al.</i> , A T <sub>H</sub> 1-T <sub>H</sub> 2 switch is a critical step in the etiology of HIV infection, <u>Immunology Today</u> <b>14.3</b> : 107-111 (1993)
EG	David <i>et al.</i> , Continuous production of carcinoembryonic antigen in hollow giber cell culture units: Brief communication, <u>J. Natl. Cancer Inst.</u> <b>60.2</b> : 303-306 (Feb. 1978)
EH	Davis, J.E. <i>et al.</i> , "Mass Transfer Between Capillary Blood and Tissues", <u>Chem. Eng. J.</u> , <b>7</b> :213-225 (1974)
EI	de Carli <i>et al.</i> , Cytolytic T cells with Th1- like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy, <u>J. Clin. Endocrinol. Metabol.</u> <b>77.5</b> : 1120-1124 (1993)
EJ	De Jong <i>et al.</i> , Maturation- and differentiation-dependent responsiveness of human CD4 <sup>+</sup> T helper subsets, <u>J. Immunol.</u> <b>149</b> : 2795-2802 (Oct. 1992)
EK	Del Prete <i>et al.</i> , High potential to tumor necrosis factor x (TNF-x) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: A peculiar feature of destructive thyroid autoimmunity, <u>Autoimmunity</u> <b>4</b> : 267-276 (1989)
EL	Del Prete <i>et al.</i> , Purified Protein derivative of <i>Mycobacterium tuberculosis</i> and excretory-secretory antigen(s) of <i>Toxocara canis</i> expand <i>in vitro</i> human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production, <u>J. Clin. Invest.</u> <b>88</b> : 346-350 (July 1991)

RECEIVED

OCT 15 2001

EXAMINER

DATE CONSIDERED


TECH CENTER 1600/2900

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EM	Derwent #008306271 WPI Acc. No. 1990-193272/199025 (citing, WO Patent Publication WO90/05541, the parent of Japanese Patent Publication No. JP 2883201, published April 19, 1999)
EN	Dillman <i>et al.</i> , Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma, <u>Cancer</u> 68: 1-8 (1991)
EO	Dillman <i>et al.</i> , Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A national biotherapy study group trial, <u>J. Clin. Oncology</u> 9.7: 1233-1240 (1991)
EP	Eastcott <i>et al.</i> , Adoptive transfer of cloned T helper cells ameliorates periodontal disease in nude rats, <u>Oral Microbiol. Immunol.</u> 9: 284-289 (1994)
EQ	Elson <i>et al.</i> , T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for T <sub>H</sub> 2 cells, <u>Internat. Immunol.</u> 6: 1003-1009 (1993)
ER	Englemann <i>et al.</i> , Activation of human T lymphocyte subsets: Helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens, <u>J. Immunol.</u> 127: 2124-2129 (1981)
ES	Faradji <i>et al.</i> , Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients, <u>J. Immunol. Meth.</u> 174: 297-309 (1994)
ET	Fiorentino <i>et al.</i> , Two types of mouse T helper cell, <u>J. Exp. Med.</u> 170: 2081-2095 (1989)
EU	Firestein <i>et al.</i> , A new murine CD4 <sup>+</sup> T cell subset with an unrestricted cytokine profile, <u>J. Immunol.</u> 143: 518-525 (1989)
EV	Foon <i>et al.</i> , Renal cell carcinoma treated with continuous-infusion interleukin-2 with <i>ex vivo</i> -activated killer cells, <u>J. Immunotherapy</u> 11: 184-190 (1992)
EW	Foulis <i>et al.</i> , Insulinitis in type 1 (insulin-dependent) diabetes mellitus in Man-macrophages, lymphocytes, and interferon- $\gamma$ containing cells, <u>J. Pathol.</u> 165: 97-103 (1991)
EX	Fowell <i>et al.</i> , Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 <sup>+</sup> T cell subset that inhibits this autoimmune potential, <u>J. Exp. Med.</u> 177: 627-636 (1993)
EY	Fowler <i>et al.</i> , Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice, <u>Advances in Bone Marrow Purging and Processing: Fourth International Symposium</u> , 533-540 (1994)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EZ	Freedman <i>et al.</i> , Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial, <u>J. Immunol.</u> <b>16</b> : 198-210 (1994)
FA	Galandrini <i>et al.</i> , Antibodies to CD44 trigger effector functions of human T cell clones, <u>J. Immunol.</u> <b>150</b> : 4225-4235 (1993)
FB	Gaudernack <i>et al.</i> , Isolation of pure functionally active CD8 <sup>+</sup> T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres, <u>J. Immun. Meth.</u> <b>90</b> : 179-187 (1986)
FC	Goedegbuure <i>et al.</i> , Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study, <u>J. Clin. Oncol.</u> <b>13</b> : 1939-1949 (1995)
FD	Gold <i>et al.</i> , Adoptive Tumor immunotherapy using human CD4 <sup>+</sup> T-cells, <u>Br. J. Cancer</u> <b>67</b> : 865 (1993)
FE	Gold <i>et al.</i> , Autolymphocyte therapy, <u>J. Surgical Res.</u> <b>59</b> : 270-286 (1995)
FF	Grabbe <i>et al.</i> , Dendritic cells as initiators of tumor immune responses: A Possible strategy for tumor immunotherapy, <u>Immunology Today</u> <b>16</b> : 117-121 (1995)
FG	Graham <i>et al.</i> , The use of <i>ex vivo</i> -activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study, <u>Seminars in Urology</u> <b>11</b> : 27-34 (1993)
FH	Grau <i>et al.</i> , Implications of cytokines in immunopathology: Experimental and clinical data, <u>Eur. Cytokine Net.</u> <b>1</b> : 203-210 (1990)
FI	Grimm <i>et al.</i> , Lymphokine-activated killer cell phenomenon, <u>J. Exp. Med.</u> <b>155</b> : 1823-1841 (1982)
FJ	Gullino <i>et al.</i> , Tissue culture on artificial capillaries, <u>Meth. Enzymol.</u> <b>58</b> : 178-184 (1979)
FK	Hager <i>et al.</i> , Tumor-associated antigens produced by mouse mammary tumor cells in artificial capillary culture, <u>J. Natl. Cancer Inst.</u> <b>69</b> : 1359-1365 (1982)
FL	Hammel <i>et al.</i> , Effect of interleukin-1 $\alpha$ on the <i>in vitro</i> activation of tumor-draining lymph node cells for adoptive immunotherapy, <u>J. Immunotherapy</u> <b>16</b> : 1-12 (1993)
FM	Hansen <i>et al.</i> , Monoclonal antibodies identifying a novel T-cell antigen and Ia antigen of human lymphocytes, <u>Immunogenetics</u> <b>10</b> : 247-260 (1980)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS  
TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FN	Hara <i>et al.</i> , Human T cell activation, <u>J. Exp. Med.</u> 161: 1513-1524 (1985)
FO	Henschler <i>et al.</i> , Maintenance of transplantation potential in <i>ex vivo</i> expanded CD34 <sup>+</sup> - selected human peripheral blood progenitor cells, <u>Blood</u> 84: 2898-2903 (1994)
FP	Herberman <i>et al.</i> , Adoptive therapy with purified CD8 cells in HIV infection, <u>AIDS/Cancer Therapies</u> , 35-44.
FQ	Ho <i>et al.</i> , A phase 1 study of adoptive transfer of autologous CD8 <sup>+</sup> lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS, <u>Blood</u> 81: 2093-2101 (1993)
FR	Hsieh <i>et al.</i> , Differential regulation of T helper phenotype development by interleukins 4 and 10 in an $\alpha\beta$ T-cell-receptor transgenic system, <u>Proc. Natl. Acad. Sci. USA</u> 89: 6065-6089 (1992).
FS	Huet <i>et al.</i> , T cell activation via CD2 [T, gp50]: The role of accessory cells in activating resting T cells via CD2, <u>J. Immunol.</u> 137: 1420-1428 (1986)
FT	Igletseme <i>et al.</i> , Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, TH <sub>1</sub> Lymphocyte clone, <u>Regional Immunology</u> 5: 317-324 (1993)
FU	Jensen <i>et al.</i> , Production of anchorage-dependent cells-problems and their possible solutions, <u>Biotechnol. Bioeng.</u> 23: 2703-2716 (1981)
FV	June <i>et al.</i> , "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", <u>Molecular and Cell Biology</u> , Dec: 4472-4481 (1987)
FW	Klimas <i>et al.</i> , Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion, <u>AIDS</u> 8: 1073-1081 (1994)
FX	Knazek <i>et al.</i> , Cell culture on artificial capillaries: An approach to tissue growth <i>in vitro</i> , <u>Science</u> 173: 65-67 (1972)
FY	Knazek <i>et al.</i> , Hormone production by cells grown in vitro on artificial capillaries, <u>Exp. Cell Res.</u> 84: 251-254 (1974)
FZ	Knazek <i>et al.</i> , Brief communication: Formation of solid human mammary carcinoma <i>in vitro</i> , <u>J. Natl. Cancer Inst.</u> 58: 419-422 (1977)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GA	Koretz <i>et al.</i> , Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer, <u>Arch. Surg.</u> 126: 898-903 (1991)
GB	Lane <i>et al.</i> , Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation, <u>Blood</u> 85: 275-282 (1995)
GC	Lea <i>et al.</i> , Characterization of human mononuclear cells after positive selection with immunomagnetic particles, <u>Scand. J. Immunol.</u> 23: 509-519 (1986)
GD	Lea <i>et al.</i> , Magnetic Monosized polymer particles for fast and specific fractionation of human mononuclear cells, <u>Scan. J. Immunol.</u> 22: 207-216 (1985)
GE	Ledbetter <i>et al.</i> , Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells, <u>J. Immunol.</u> 135: 2331-2336 (1985)
GF	Ledbetter <i>et al.</i> , Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression, <u>J. Immunol.</u> 135: 1819-1825 (1985)
GG	Ledbetter <i>et al.</i> , Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor, <u>Eur. J. Immunol.</u> 18: 525-532 (1988)
GH	Liblau <i>et al.</i> , Th1 and Th2 CD4 <sup>+</sup> T Cells in the pathogenesis of organ-specific autoimmune diseases, <u>Immunology Today</u> 16: 34-38 (1995)
GI	Lindqvist <i>et al.</i> , Enhanced IL-4-mediated D10.G4.1 Proliferation with suboptimal concentrations of anti-IL-4 receptor Monoclonal antibodies, <u>J. Immunol.</u> 150: 394-398 (1993)
GJ	Lum <i>et al.</i> , In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen, <u>Cell. Immunol.</u> 72: 122-129 (1982)
GK	Luyten <i>et al.</i> , Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation, <u>J. Biol. Chem.</u> 264(23):13377-13380 (1989)
GL	Lynch <i>et al.</i> , Interleukin 7 promotes long-term <i>in vitro</i> growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy <i>in vivo</i> , <u>J. Exp. Med.</u> 179: 31-42 (1994)
GM	Manetti <i>et al.</i> , CD30 expression by CD8 <sup>+</sup> T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 <sup>+</sup> CD30 <sup>+</sup> T cell clones in human immunodeficiency virus infection, <u>J. Exp. Med.</u> 180: 2407-2411 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GN	Manger <i>et al.</i> , T cell activation: Differences in the signals required for IL 2 Production by nonactivated and activated T cells, <u>J. Immunol.</u> 135: 3669-3673 (1985)
GO	Marcus <i>et al.</i> , The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced <i>in vivo</i> antitumor activity, <u>J. Immunotherapy</u> 15: 105-112 (1994)
GP	Martin <i>et al.</i> , "A 44 Kilodalton Cell Surface Homodimer Regulates Interleukin 2 Production By Activated Human T Lymphocytes", <u>J. of Immunol.</u> 136(9): 3282-3287 (1986)
GQ	Mastsumura <i>et al.</i> , Characteristics and <i>in vivo</i> homing of long-term T-cell Lines and clones derived from tumor-draining lymph nodes, <u>Cancer Res.</u> 54: 2744-2750 (1994)
GR	Miller <i>et al.</i> , Large scale <i>ex vivo</i> expansion and activation of human natural killer cells for autologous therapy, <u>Bone Marrow Transplantation</u> 14: 555-562 (1994)
GS	Mosmann <i>et al.</i> , TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties, <u>Ann. Rev. Immunology</u> 7: 145-173 (1989)
GT	Mosmann <i>et al.</i> , The expanding universe of T-cell subset: Th1, Th2 and more, <u>Immunology Today</u> (March 1996).
GU	Mosmann <i>et al.</i> , Two types of murine helper T cell clone, <u>J. Immunol.</u> 136: 2348-2357 (1986)
GV	Mulder <i>et al.</i> , Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity, <u>Cancer Immunol. Immunother.</u> 41: 293-301 (1995)
GW	Nabel <i>et al.</i> , An inducible transcription factor activates expression of human immunodeficiency virus in T cells, <u>Nature</u> , 326:711-3 (1987)
GX	Nagler <i>et al.</i> , Red blood cell depletion and enrichment of CD34 <sup>+</sup> Hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD34 immunoselection, <u>Exp. Hematol.</u> 22: 1134-1140 (1994)
GY	Nakajima <i>et al.</i> , Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression, <u>Proc. Natl. Acad. Sci. USA</u> 91: 7889-7893 (1994)
GZ	Niessner <i>et al.</i> , Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR), <u>Clin. Exp. Immunol.</u> 101: 428-435 (1995)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HA	O'Garra <i>et al.</i> , Role of cytokines in determining T-lymphocyte function, <u>Immunology</u> 6: 458-466 (1994)
HB	Ohno <i>et al.</i> , Lectin-activated Killer cells rapidly induced by pokeweed mitogen conjugated beads and their <i>in vivo</i> antitumor effects, <u>Int. J. Immunopharmacol.</u> 16: 761-768 (1994)
HC	Okamoto <i>et al.</i> , The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells, <u>Cancer Immunol. Immunother</u> 40: 173-181 (1995)
HD	Okarma <i>et al.</i> , The AIS collector: A new technology for stem cell purification, <u>Advances in Bone Marrow Purging and Processing</u> 487-504 (1992)
HE	Oxholm <i>et al.</i> , Cytokine expression in labial salivary glands from patients with primary Sjogrens syndrome, <u>Autoimmunity</u> 12: 185-191 (1992)
HF	Palliard <i>et al.</i> , Simultaneous production of IL-2, IL-4, and IFN- $\mu$ by activated human CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell clones, <u>J. Immunol.</u> 141: 849-855 (1988)
HG	Pierrès <i>et al.</i> , Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation, <u>Eur. J. Immunol.</u> 18: 685-690 (1988)
HH	Polanski <i>et al.</i> , Differentiation of Th2 cells from precursors in ra peripheral blood, ( <u>submitted</u> 1996)
HI	Powrie <i>et al.</i> , Regulatory interactions between CD45RB <sup>high</sup> and CD45RB <sup>low</sup> CD4 <sup>+</sup> T cells are important for the balance between protective and pathogenic cell-mediated immunity, <u>J. Exp. Med.</u> 179: 589-600 (1994)
HJ	Puchetti <i>et al.</i> , A T <sub>H</sub> 1-T <sub>H</sub> 2-like switch in candidiasis: New perspectives for therapy, <u>Trends Microbiol.</u> 3(6): 237-240 (1995)
HK	Quayle <i>et al.</i> , Rheumatoid inflammatory T-cell clones express mostly Th-1 but also Th2 and mixed (Th0-like) cytokine patterns, <u>Scand. J. Immunol.</u> 38: 75-82 (1993)
HL	Reinherz <i>et al.</i> , Separation of functional subsets of human T cells by a monoclonal antibody, <u>Proc. Natl. Acad. Sci. USA</u> 76: 4061-4065 (1979)
HM	Riddell <i>et al.</i> , Principles for adoptive T cell therapy of human viral diseases, <u>Ann. Rev. Immunology</u> 13: 545-586 (1995)
HN	Riddell <i>et al.</i> , Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, <u>Science</u> 257: 238-241 (1992)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  	ATTY. DOCKET NO. 24731-500G	SERIAL NO. 09/824,906	RECEIVED OCT 15 2001 TECH CENTER 1600/2900
	APPLICANT GRUENBERG		
	FILING DATE April 2, 2001	GROUP 1644	

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HO	Riddell <i>et al.</i> , CD8 + cytotoxic T cell therapy of cytomegalovirus and HIV infection, <u>Immunology</u> 5: 484-491 (1993)
HP	Romagnani <i>et al.</i> , Regulation of the development of type 2 T-helper cells in allergy, <u>Immunology</u> 6: 838-846 (1994)
HQ	Romagnani <i>et al.</i> , HIV can induce a T <sub>H</sub> 1 to T <sub>H</sub> 0 shift, and preferentially replicates in CD4 <sup>+</sup> T-cell clones producing T <sub>H</sub> 2-type cytokines, <u>60th Forum in Immunology</u> , 611-617 (1994)
HR	Romani <i>et al.</i> , Proliferating dendritic cell progenitors in human blood, <u>J. Exp. Med.</u> 180: 83-93, (1994).
HS	Romani <i>et al.</i> , Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance, <u>Infection and Immunity</u> 59: 4647-4654 (1991)
HT	Rosenberg <i>et al.</i> , Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, <u>N. Engl. J. Med.</u> 313: 1485-1492 (1985)
HU	Rosenberg <i>et al.</i> , A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, <u>N. Engl. J. Med.</u> 316: 889-897 (1987)
HV	Rosenberg <i>et al.</i> , Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, <u>N. Engl. J. Med.</u> 319: 1676-1680 (1988)
HW	Rutzky <i>et al.</i> , Human colon adenocarcinoma cells. III. <i>In vitro</i> organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture, <u>J. Natl. Cancer Inst.</u> 63: 85-93 (1979)
HX	Sacchi <i>et al.</i> , Induction of tumor regression in experimental model of human head and neck cancer by human A-Lak cells and IL-2, <u>Int. J. Cancer</u> , 47: 784-791 (1991)
HY	Salgaller <i>et al.</i> , Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides, <u>Cancer Res.</u> 55: 4972-4979 (1995)
HZ	Saoudi <i>et al.</i> , TH2 activated cells prevent experiential autoimmune unweoretinitis, a TH1-dependent autoimmune disease, <u>Eur. J. Immunol.</u> 23: 3096-3103 (1993)
IA	Scott <i>et al.</i> , The role of T-cell subsets and cytokines in the regulation of infection, <u>Immunology Today</u> , 12: 346-348, (1991).

EXAMINER	DATE CONSIDERED
----------	-----------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

RECEIVED

OCT 15 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IB	Scott, P. <i>et al.</i> , "Role of Cytokines and CD4 + T-Cell Subsets in the Regulation of Parasite Immunity and Disease", <u>Immunol. Rev.</u> , 112:161-182 (1989)
IC	Seder <i>et al.</i> , Interleukin 12 acts directly on CD4 + T cells to enhance priming for interferon $\mu$ production and diminishes interleukin 4 inhibition of such priming, <u>Proc. Natl. Acad. Sci. USA</u> 90: 10188-10192 (1993)
ID	Sedlmayr <i>et al.</i> , Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells, <u>J. Immunotherapy</u> 10: 336-346 (1991)
IE	Shanafelt <i>et al.</i> , Costimulatory signals can selectively modulate cytokine production by subsets of CD4 <sup>+</sup> T cells, <u>J. Immunol.</u> 154: 1684-1690 (1995).
IF	Sher <i>et al.</i> , Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection, <u>Immunological Rev.</u> 127: 183-204 (1992).
IG	Shimizu <i>et al.</i> , Costimulation of proliferative responses of resting CD4 <sup>+</sup> T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin, <u>J. Immunol.</u> 145: 59-67 (1990)
IH	Simon <i>et al.</i> , Divergent T-cell cytokine patterns in inflammatory arthritis, <u>Proc. Natl. Acad. Sci. USA</u> 91: 8562-8566 (1994)
II	Spertini <i>et al.</i> , Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells, <u>J. Immunol.</u> 149: 65-70 (1992)
IJ	Springer <i>et al.</i> , Adhesion receptors of the immune system, <u>Nature</u> 346: 425-434 (1990)
IK	Sugie <i>et al.</i> , Stimulation of NK-like YT cells via leukocyte function-associated antigen (LFA)-1, <u>J. Immunol.</u> 154: 1691-1698 (1995)
IL	Swabb <i>et al.</i> , Diffusion and convection in normal and neoplastic tissues, <u>Cancer Res.</u> 34: 2814-2814 (1974)
IM	Sznol <i>et al.</i> , Adoptive immunotherapy, <u>Cancer Chemotherapy and Biological Responses Modifiers Annual</u> 14: 227-248 (1993)
IN	Takahashi <i>et al.</i> , Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion, <u>Jpn. J. Cancer Res.</u> 86: 861-866 (1995)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IO	Tamura <i>et al.</i> , T cell activation through TCR/CD3 complex IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage, <u>J. Immunol.</u> 148: 2370-2377 (1992)
IP	Translation (not certified) of the Claims for the Japanese Patent No. 2883201
IQ	Tax <i>et al.</i> , Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells, <u>Nature</u> 304: 445-447 (1983)
IR	Thompson <i>et al.</i> , Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma, <u>J. Clin. Oncol.</u> 10: 960-968 (1992)
IS	Thygesen <i>et al.</i> , Immunity to experimental <i>Salmonella typhimurium</i> infections in rats, <u>APMIS</u> 102: 489-494 (1994)
IT	Torpey, Effects of adoptive immunotherapy with autologous VS8 + T lymphocytes on immunologic parameters: Lymphocyte subsets and cytotoxic, <u>Clinical Immunol. Immunopathol.</u> 68: 263-272 (1993)
IU	Toso, J.F. <i>et al.</i> , "MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-Specific Activation", <u>Cancer Res.</u> , 56:16-20 (1996)
IV	Turner <i>et al.</i> , Human T cells from autoimmune and normal individuals can produce tumor necrosis factor, <u>Eur. J. Immunol.</u> 17: 1807-1814 (1987)
IW	Tze <i>et al.</i> , Long-term survival of adult rat islets of Langerhans in artificial capillary culture units, <u>Diabetes</u> , 26: 185-191 (1977)
IX	Urban <i>et al.</i> , The importance of Th2 cytokines in protective immunity to nematodes, <u>Immunological Reviews</u> , 127: 205-220 (1992)
IY	Utsugi <i>et al.</i> , Prevention of recurrent diabetes in syngeneic islet-transplanted NOD Mice by transfusion of autoreactive T lymphocytes, <u>Transplantation</u> 57: 1799-1804 (1994)
IZ	Van Lier <i>et al.</i> , Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen, <u>J. Immunol.</u> 139: 1589-1596 (1987)
JA	Van Lunzen <i>et al.</i> , Investigations on autologous T-cells for adoptive immunotherapy of AIDS, <u>Cell Activation and Apoptosis in HIV Infection</u> , 6: 57-70 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed:

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.  
24731-500GSERIAL NO.  
09/824,906APPLICANT  
GRUENBERGFILING DATE  
April 2, 2001GROUP  
1644

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JB	Vandenberghe <i>et al.</i> , Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: Evidence for signal transduction through CD5, <u>Eur. J. Immunol.</u> <b>21</b> : 251-259 (1991)
JC	Whiteside <i>et al.</i> , Generation and characterization of <i>ex vivo</i> propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus, <u>Blood</u> , <b>81</b> : 2085-2092 (1993)
JD	Wolf <i>et al.</i> , Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries, <u>Tran. Amer. Soc. Artif. Int. Organs.</u> <b>21</b> : 16-27 (1975)
JE	Yamamura <i>et al.</i> , Defining protective responses to pathogens: Cytokine profiles in leprosy lesions, <u>Science</u> <b>254</b> : 277-279 (1991)
JF	Yang <i>et al.</i> , <i>In vitro</i> priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation, <u>J. Immunol.</u> <b>155</b> : 3897-3903 (1995)
JG	Yannelli <i>et al.</i> , The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer, <u>Journal of Immunological Methods</u> <b>139</b> : 1-16 (1991)
JH	Zhang <i>et al.</i> , T-cell cytokine responses in human infection with <i>Mycobacterium tuberculosis</i> , <u>Infectious Immunology</u> : 3231-3234 (1995)

RECEIVED

OCT 10 2001

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: AUTOLOGOUS IMMUNE CELL THERAPY: CELL COMPOSITIONS, METHODS AND APPLICATIONS TO TREATMENT OF HUMAN DISEASE

Date mailed: